Opendata, web and dolomites

BoVLP-BVD SIGNED

Tagged (DIVA) polyantigenic vaccine against Bovine Viral Diarrhea virus (BVDv) based on virus-Like-Particles

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BoVLP-BVD project word cloud

Explore the words cloud of the BoVLP-BVD project. It provides you a very rough idea of what is the project "BoVLP-BVD" about.

agent    suboptimal    reduce    viral    efficacy    diva    instrument    hundreds    persistent    demonstrating    infection    candidate    positive    exposed    licensed    attributes    cyl    infectious    sme    livestock    million    prototype       agreements    774994    systematic    euros    patented    countries    had    trl6    virus    25    stage    prevent    veterinarian    of    commercial    commercialisation    diseases    antibiotics    approximately    vivo    public    final    fight    food    feasibility    pressure    bvd    investment    business    50    ordm    recombinant    industrial    species    diarrhea    rate    safety    multiplier    data    context    agro    biotech    economic    oacute    lifetime    vaccine    royalties    cattle    projections    endemic    productivity    company    90    herd    trl8    milestones    complete    animal    disease    regulatory    social    5x    point    environmental    internal    vaccines    aquil    herds    becomes    industry    hut    animals    demonstrated    pharmaceutical    worldwide    return    bovine    bvdv    programs    reproduction    particle    eradication    bodies    manufacturing    vaccination   

Project "BoVLP-BVD" data sheet

The following table provides information about the project.

Coordinator
AQUILON CYL SOCIEDAD LIMITADA 

Organization address
address: LUGAR FACULTAD DE VETERINARIA S/N CAMPUS VEGAZANA
city: LEON
postcode: 24000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙221˙042 €
 EC max contribution 1˙554˙729 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AQUILON CYL SOCIEDAD LIMITADA ES (LEON) coordinator 1˙554˙729.00

Map

 Project objective

In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime. Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals. Aquilón CyL, a leading biotech company, has developed new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. Aquilón has demonstrated the technical, commercial and regulatory feasibility by the SME instrument phase 1 project (nº 774994). After developing the vaccine to TRL6 stage (pre-industrial prototype with positive activity data), Aquilón will develop one vaccine to TRL8 stage, demonstrating the commercial-scale manufacturing and in-vivo safety, efficacy and DIVA attributes in the target species. This vaccine candidate will be licensed to one or more veterinarian pharmaceutical company that will complete the final field studies required for commercialisation. Our business projections, based on agreements with Development milestones and commercial royalties, show potential for a 5X investment multiplier with a 25% internal rate of return.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BOVLP-BVD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BOVLP-BVD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More